Princeton-based Bristol-Myers Squibb and Korea-based Samsung BioLogics announced a 10-year agreement today, under which Samsung will manufacture a commercial antibody cancer drug for Bristol-Myers at its recently completed plant in South Korea.
Financial terms were not disclosed.
According to the announcement, technology transfer and trial production will commence this week, and commercial production will immediately begin following regulatory approvals.
Digital content editor Joe Ross is @joeross on Twitter.
Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.View Comment Policy